Our Interventional Urology North America reporting unit is at risk for future goodwill impairment charges, which could be material, if there is a deterioration in general economic, market or business conditions or significant unfavorable changes in our forecasted current or long-term revenue growth rates, operating margins and/or discount rate.


	Gross Carrying Amount				Accumulated Amortization
	March 30, 2025		December 31, 2024		March 30, 2025		December 31, 2024
Customer relationships	$	1,357,702	$	1,354,087	$	(638,736)	$	(620,619)
In-process research and development	23,666		23,666		—		—
Intellectual property	1,873,419		1,870,407		(892,306)		(863,066)
Distribution rights	23,207		23,004		(22,921)		(22,524)
Trade names	605,210		603,202		(103,097)		(99,443)
Non-compete agreements	21,904		21,894		(21,904)		(21,894)
	$	3,905,108	$	3,896,260	$	(1,678,964)	$	(1,627,546)

We test the recoverability of long-lived assets whenever events or circumstances indicate the carrying value of an asset may not be recoverable. As of March 30, 2025, we identified indicators of a potential impairment related to the long-lived assets associated with our Titan SGS asset group, which primarily consists of intangible assets. The indicators of a potential impairment primarily arose from lower than expected sales of our Titan SGS product line and anticipated continuing reduced demand for bariatric surgery procedures in future periods driven by the growing adoption of GLP-1 products. We performed a recoverability test, utilizing an updated long-term forecast reflecting higher uncertainty of revenue growth in future periods compared to previous estimates. We concluded that the undiscounted cash flows of the Titan SGS product line exceeded the carrying value of the related assets by approximately 10% and no impairment was recognized. If actual future revenues are lower than forecasted, it may result in future impairment charges, which could be material. The carrying value of the intangible assets as of March 30, 2025 was $130.0 million.